GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NuCana PLC (NAS:NCNA) » Definitions » PensionAndRetirementBenefit

NCNA (NuCana) PensionAndRetirementBenefit : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NuCana PensionAndRetirementBenefit?

NuCana's PensionAndRetirementBenefit for the quarter that ended in Sep. 2024 was $0.00 Mil.


NuCana PensionAndRetirementBenefit Historical Data

The historical data trend for NuCana's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuCana PensionAndRetirementBenefit Chart

NuCana Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
Get a 7-Day Free Trial Premium Member Only - - - - -

NuCana Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NuCana PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


NuCana Business Description

Industry
Traded in Other Exchanges
Address
3 Lochside Way, Edinburgh, GBR, EH12 9DT
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.